Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease
The DOI matches its Crossref record; 204 of the 206 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD), the most common cause of dementia, is a chronic neurodegenerative disease induced by multiple factors. The high incidence and the aging of the global population make it a growing global health concern with huge implications for individuals and society. The clinical manifestations are progressive cognitive dysfunction and lack of behavioral ability, which not only seriously affect the health and quality of life of the elderly, but also bring a heavy burden to the family and society. Unfortunately, almost all the drugs targeting the classical pathogenesis have not achieved satisfactory clinical effects in the past two decades. Therefore, the present review provides more novel ideas on the complex pathophysiological mechanisms of AD, including classical pathogenesis and a variety of possible pathogenesis that have been proposed in recent years. It will be helpful to find out the key target and the effect pathway of potential drugs and mechanisms for the prevention and treatment of AD. In addition, the common animal models in AD research are outlined and we examine their prospect for the future. Finally, Phase I, II, III, and IV randomized clinical trials or on the market of drugs for AD treatment were searched in online databases (Drug Bank Online 5.0, the U.S. National Library of Medicine, and Alzforum). Therefore, this review may also provide useful information in the research and development of new AD-based drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current AD animal models have shifted from single genetic mutation models to multi-gene transgenic models, and consider non-genetic pathogenic factors and species differences to more accurately simulate the AD progression process.484–487”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [485]
Citations
Cites
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286 · cited 1×
“Finally, intestinal microorganisms ,suchasserotonin,kynurenine,melatonin, (cid:4) -aminobutyric acid, catecholamine, histamine, and acetylcholine, which can be directly involved in the regulation of the CNS [127, 128].”
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413 · cited 1×
“Through this pathway, intestinal microorganisms may affect the activation of peripheral immune cells and the distribution of cytokines, and it may also cause inflammation and damage of the whole body and CNS [131, 132].”
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“In the first half of the 1990 s, two studies revealed that fibrillar amyloid load poorly correlated with cognitive impairment [39, 40].”
Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis
Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015) · Cell · doi:10.1016/j.cell.2015.02.047 · Cited by 3,614
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“…stage of the inflammatory response, microglia surface receptors (triggering receptor expressed on myeloid cells 2, TREM2) are able to recognize damaged cells and heterologous substances in the brain, causing microglia activation and a series of down-stream effects that trigger neuroinflammation [72].”
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185 · cited 1×
“It can also promote the toxicity and aggregation of A (cid:2) , inducing apoptosis and neuronal death [86].”
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Dominy, S. S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., Nguyen, M., Haditsch, U., Raha, D., Griffin, C., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau3333 · Cited by 1,966
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1×
“There is evidence that abnormal changes in microglia is associated with AD [73].”
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846 · cited 1×
“In recent years, A (cid:2) has also been considered as an antimicrobial peptide involved in the innate immune response [133].”
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“The third type is A (cid:2) receptor antagonists, which block the downstream pathways of A (cid:2) so that A (cid:2) cannot be effectively and safely cleared, thereby exerting neurotoxic effects [181].”
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750 · cited 2×
“[85]”
Fang, E. F., Hou, Y., Palikaras, K., Adriaanse, B. A., Kerr, J. S., Yang, B., Lautrup, S., Hasan-Olive, M. M., Caponio, D., Dan, X., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0332-9 · Cited by 1,740 · cited 1×
“In addition, Ca 2 + as the second messenger, is highly correlated with nerve cell excitation, and the increase of intracellular Ca 2 + concentration will promote the increase of mitochondrial activity, an increase of ROS, and damage to nerve cells, leading to AD [83].”
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663 · cited 1×
“The products of the first pathway have a trophic and protective effect on nerve cells [27].”
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530 · cited 1×
“In 1999, two additional reports indicated that soluble non-fibrillar A (cid:2) levels correlated strongly with the severity of the disease [41] and synaptic loss [42], suggesting the possibility that soluble species of A (cid:2) might play a larger role in AD pathophysiology than deposited amyloid.”
Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease
Da Mesquita, S., Louveau, A., Vaccari, A., Smirnov, I., Cornelison, R. C., Kingsmore, K. M., Contarino, C., Onengut-Gumuscu, S., Farber, E., Raper, D., et al. (2018) · Nature · doi:10.1038/s41586-018-0368-8 · Cited by 1,445
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · cited 1×
“Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE4 carriers [140, 141].”
The global burden of neurological disorders: translating evidence into policy
Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., Deuschl, G., Parmar, P., Brainin, M., & Murray, C. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30411-9 · Cited by 1,303
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Ziv, Y., Ron, N., Butovsky, O., Landa, G., Sudai, E., Greenberg, N., Cohen, H., Kipnis, J., & Schwartz, M. (2006) · Nature Neuroscience · doi:10.1038/nn1629 · Cited by 1,209 · cited 1×
“Moreover, CNS-specific autoimmune T cells that interact with microglia are critical for plasticity and cell renewal in the adult mouse brain [66].”
Wang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., Xie, Z., Chu, X., Yang, J., Wang, H., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0216-x · Cited by 1,144
Current understanding of Alzheimer’s disease diagnosis and treatment
Weller, J., & Budson, A. (2018) · F1000Research · doi:10.12688/f1000research.14506.1 · Cited by 1,083 · cited 3×
“Although limited evidence suggests that earlier identification of AD pathology will lead to better and more-definitive treatment, the results of larger-scale interventions are not yet available for review [5].”
InfluentialRoles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003 · cited 2×
“Its six subtypes can perform a variety of post-translational modifications, interact with various proteins, and perform a variety of biological functions in the brain [50].”
Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000 · cited 1×
“However, with the deepening of AD research in recent years, more and more histopathology and radiographic imaging have shown that the formation of amyloid plaques is not well related to the occurrence of AD, and soluble A (cid:2) oligomers are the key factors to exert neurotoxicity [37, 38].”
Kumar, D. K. V., Choi, S. H., Washicosky, K. J., Eimer, W. A., Tucker, S., Ghofrani, J., Lefkowitz, A., McColl, G., Goldstein, L. E., Tanzi, R. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1059 · Cited by 971 · cited 1×
“…a new idea that the production of A (cid:2) may be a spontaneous self-protective behavior of the body, which may not be the initiator of AD but the result of the central nervous system (CNS) defense against external infections, and long-term high levels of A (cid:2) can induce AD production [25].”
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969 · cited 1×
“However, most of these inhibitors were terminated in pre-clinical or clinical trials due to poor selectivity or difficulty in passing through the BBB [177].”
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Dementia in China: epidemiology, clinical management, and research advances
Jia, L., Quan, M., Fu, Y., Zhao, T., Li, Y., Wei, C., Tang, Y., Qin, Q., Wang, F., Qiao, Y., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30290-x · Cited by 875 · cited 1×
“…on prevention, that is, the first-level prevention and control based on the risk factors of AD induced by intervention, the second-level based on improving or delaying the symptoms of AD, and the third-level based on intervention of AD from the perspective of psychology-society-environment [224].”
Self-citationThe Gut Microbiota and Alzheimer’s Disease
Jiang, C., Li, G., Huang, P., Liu, Z., & Zhao, B. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161141 · Cited by 852 · cited 1×
“…example, when the intestinal flora is disordered, especially when Lactobacillus , Bifidobacterium , Streptococcus , and Lactococcus are reduced, the level of (cid:4) -aminobutyric acid in the intestinal and CNS will be decreased, which result in inhibitory synaptic dysfunction and impairment [129].”
Brain-Gut-Microbiota Axis in Alzheimer’s Disease
Kowalski, K., & Mulak, A. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18087 · Cited by 826
Artemisinin—A Gift from Traditional Chinese Medicine to the World (Nobel Lecture)
Tu, Y. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601967 · Cited by 810 · cited 1×
“In 2015, William C. Campbell, Satoshi ¯Omura, and Tu Youyou have been awarded the Nobel Prize in Physiology or Medicine [210].”
The cost of Alzheimer's disease in China and re‐estimation of costs worldwide
Jia, J., Wei, C., Chen, S., Li, F., Tang, Y., Qin, W., Zhao, L., Jin, H., Xu, H., Wang, F., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.12.006 · Cited by 752 · cited 1×
“In the next decade, the sales will double from $818 billion in 2015, and the market scale of AD drugs will continue to expand [15].”
Self-citationThe amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Interaction between Aβ and Tau in the Pathogenesis of Alzheimer’s Disease
Zhang, H., Wei, W., Zhao, M., Ma, L., Jiang, X., Pei, H., Cao, Y., & Li, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.57078 · Cited by 689 · cited 1×
“Therefore, some researchers have proposed that in the pathogenesis of AD, hyperphosphorylated tau interacts with abnormal deposition of A (cid:2) , and both are involved in the course of AD [59].”
Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes
Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., Kyrargyri, V., Pfeiffer, T., Khennouf, L., Madry, C., et al. (2019) · Science · doi:10.1126/science.aav9518 · Cited by 682 · cited 1×
“Studies have shown that A (cid:2) deposition causes cerebral vasoconstriction in AD patients by about 8.1% [108], reducing cerebral blood flow by 50%, energy supply, and gray matter blood flow by 42%.”
InfluentialEimer, W. A., Vijaya Kumar, D. K., Navalpur Shanmugam, N. K., Rodriguez, A. S., Mitchell, T., Washicosky, K. J., György, B., Breakefield, X. O., Tanzi, R. E., & Moir, R. D. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.030 · Cited by 674
Alzheimer’s Disease: Past, Present, and Future
Bondi, M. W., Edmonds, E. C., & Salmon, D. P. (2017) · Journal of the International Neuropsychological Society · doi:10.1017/s135561771700100x · Cited by 649
Regulation of inflammation by microbiota interactions with the host
Blander, J. M., Longman, R. S., Iliev, I. D., Sonnenberg, G. F., & Artis, D. (2017) · Nature Immunology · doi:10.1038/ni.3780 · Cited by 646 · cited 1×
“In addition, intestinal flora disorders can reduce the expression levels of neurotrophic factors and serotonin, resulting in the dysfunction of CNS and changes in neurodegeneration [130].”
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630 · cited 1×
“Itiscur-rentlyinphaseIclinicaltrials[173].”
Molecular genetics of early-onset Alzheimer’s disease revisited
Cacace, R., Sleegers, K., & Van Broeckhoven, C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.012 · Cited by 617 · cited 1×
“EOAD accounts for 1%–5% of all cases and is mainly related to gene mutations in apolipoprotein E ( APOE ), APP , PS1/2 , and other genes [136, 137].”
Structural characterization of the core of the paired helical filament of Alzheimer disease.
Wischik, C. M., Novak, M., Edwards, P. C., Klug, A., Tichelaar, W., & Crowther, R. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4884 · Cited by 595 · cited 1×
“In 1988, Wischik et al. [54] isolated tau from the brain plaques of AD patients, and firstly proved that tau may be the cause of dementia.”
Sochocka, M., Donskow-Łysoniewska, K., Diniz, B. S., Kurpas, D., Brzozowska, E., & Leszek, J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1188-4 · Cited by 584
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559 · cited 1×
“According to the vascular mechanism [107], there are A (cid:2) deposits in the adventitia and media of the cerebral cortex and leptomeninges in AD patients, which aggravates cerebral vasospasm, the insufficient blood supply to brain tissue, reduces the ability to clear A (cid:2) , and eventually…”
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557
Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease
Reddy, P. H., & Oliver, D. M. (2019) · Cells · doi:10.3390/cells8050488 · Cited by 496
Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease
Kesika, P., Suganthy, N., Sivamaruthi, B. S., & Chaiyasut, C. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118627 · Cited by 479 · cited 1×
“Finally, intestinal microorganisms ,suchasserotonin,kynurenine,melatonin, (cid:4) -aminobutyric acid, catecholamine, histamine, and acetylcholine, which can be directly involved in the regulation of the CNS [127, 128].”
Periodontitis and Cognitive Decline in Alzheimer’s Disease
Ide, M., Harris, M., Stevens, A., Sussams, R., Hopkins, V., Culliford, D., Fuller, J., Ibbett, P., Raybould, R., Thomas, R., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151081 · Cited by 461
The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease
Minter, M. R., Taylor, J. M., & Crack, P. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13411 · Cited by 451
Perez Ortiz, J. M., & Swerdlow, R. H. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14585 · Cited by 426 · cited 1×
“Therefore, mitochondrial dysfunction can seriously affect the normal operation of the brain and is closely related to the occurrence and development of AD [80].”
Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
Correlations of synaptic and pathological markers with cognition of the elderly
Dickson, D. W., Crystal, H. A., Bevona, C., Honer, W., Vincent, I., & Davies, P. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00013-5 · Cited by 410 · cited 1×
“In the first half of the 1990 s, two studies revealed that fibrillar amyloid load poorly correlated with cognitive impairment [39, 40].”
Autophagy in Alzheimer’s disease pathogenesis: Therapeutic potential and future perspectives
Zhang, Z., Yang, X., Song, Y.-Q., & Tu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101464 · Cited by 369
Establishment of the mimetic aging effect in mice caused by D-galactose
Ho, S.-C., Liu, J.-H., & Wu, R.-Y. (2003) · Biogerontology · doi:10.1023/a:1022417102206 · Cited by 359 · cited 1×
“[157]”
Soluble Aβ oligomer production and toxicity
Larson, M. E., & Lesné, S. E. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07478.x · Cited by 356
Schwartz, M., & Baruch, K. (2014) · The EMBO Journal · doi:10.1002/embj.201386609 · Cited by 349 · cited 1×
“Schwartz and Baruch [68] found that peripheral immune cells, including T cells, could be detected in brain lesions, and they speculated that peripheral immune cells could also reach the lesion site and cause pathological changes during the development of AD.”
Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration
Tracy, T. E., Madero-Pérez, J., Swaney, D. L., Chang, T. S., Moritz, M., Konrad, C., Ward, M. E., Stevenson, E., Hüttenhain, R., Kauwe, G., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.041 · Cited by 342
Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy
Wang, C., Fan, L., Khawaja, R. R., Liu, B., Zhan, L., Kodama, L., Chin, M., Li, Y., Le, D., Zhou, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29552-6 · Cited by 333
Hodson, R. (2018) · Nature · doi:10.1038/d41586-018-05717-6 · Cited by 320
Marlatt, M. W., Potter, M. C., Lucassen, P. J., & van Praag, H. (2012) · Developmental Neurobiology · doi:10.1002/dneu.22009 · Cited by 314 · cited 1×
“The increase of neurogenesis in the dentate gyrus after exercise is related to the enhancement of spatial memory, and the inhibition of neurogenesis by local gamma irradiation in the hippocampus eliminates the improvement of spatial learning and memory by exercise stimulation [216, 217].”
Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage
Shafiei, S. S., Guerrero-Muñoz, M. J., & Castillo-Carranza, D. L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00083 · Cited by 314 · cited 1×
“Studies have shown that smaller soluble tau may be more damaging than NFT, which not only contributes to the diffusion of pathological tau but also can lead to neuronal degeneration and affect cognition [56].”
Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review
de la Monte, S. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.008 · Cited by 313 · cited 1×
“Recent studies have confirmed that insulin not only plays a role in the peripheral circulation, but also widely exists in the CNS, and has a role in regulating cognition [90].”
Genes associated with Alzheimer's disease: an overview and current status
Giri, M., Lü, Y., & Zhang, M. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s105769 · Cited by 311
Ma, N., Zhang, Z., Liao, F., Jiang, T., & Tu, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107658 · Cited by 310 · cited 1×
“As the strongest support, artemisinin, a highly effective drug found in Artemisia annuloides to treat malaria, has saved millions of lives around the world, especially in developing countries [209].”
γ-Secretase in Alzheimer’s disease
Hur, J.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00754-8 · Cited by 310
Molecular landscapes of human hippocampal immature neurons across lifespan
Zhou, Y., Su, Y., Li, S., Kennedy, B. C., Zhang, D. Y., Bond, A. M., Sun, Y., Jacob, F., Lu, L., Hu, P., et al. (2022) · Nature · doi:10.1038/s41586-022-04912-w · Cited by 302 · cited 1×
“…that the content of synaptic protein in hippocampal neurons of AD patients is significantly lower than that of normal people, and the severity of the loss of cortical synapses and hippocampal synapses in the brain of AD patients is positively correlated with the degree of clinical dementia [97].”
Resolution of inflammation is altered in Alzheimer's disease
Wang, X., Zhu, M., Hjorth, E., Cortés‐Toro, V., Eyjolfsdottir, H., Graff, C., Nennesmo, I., Palmblad, J., Eriksdotter, M., Sambamurti, K., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.024 · Cited by 301
Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link
Zhang, Y., Huang, N.-Q., Yan, F., Jin, H., Zhou, S.-Y., Shi, J.-S., & Jin, F. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.11.015 · Cited by 301
Challenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291 · cited 1×
“Perhaps a series of clinical failures may question the further development of antibody-targeted drugs and the results of ongoing phase III and phase IV trials of new drugs are expected to clarify this key issue [13].”
Mouse models of Alzheimer’s disease
Esquerda-Canals, G., Montoliu-Gaya, L., Güell-Bosch, J., & Villegas, S. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170045 · Cited by 288
Dysfunction of NMDA receptors in Alzheimer’s disease
Zhang, Y., Li, P., Feng, J., & Wu, M. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2546-5 · Cited by 282 · cited 1×
“It is a cationic channel controlled by the excitatory neurotransmitter glutamate, and plays an important role in excitatory transmission, synaptic integration, learning,and memory [84].”
Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer’s disease
Otero-Garcia, M., Mahajani, S. U., Wakhloo, D., Tang, W., Xue, Y.-Q., Morabito, S., Pan, J., Oberhauser, J., Madira, A. E., Shakouri, T., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.06.021 · Cited by 262
Rodent models of neuroinflammation for Alzheimer’s disease
Nazem, A., Sankowski, R., Bacher, M., & Al-Abed, Y. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0291-y · Cited by 248
Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Athar, T., Al Balushi, K., & Khan, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06512-9 · Cited by 247 · cited 1×
“However, in the long-term treatment (more than 6 months) of mild-to-moderate patients, the effective rate of these drugs was only 50%, which is maintained for 1 to 1.5 years after stopping the drug and could not reverse the characteristics of the disease [171].”
InfluentialNeurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation
Schwartz, M., & Deczkowska, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.001 · Cited by 246 · cited 1×
“…may be beneficial to repair immune damage at the beginning, but gradually produces a chronic inflammatory state, increased production of inflammatory cytokines, free radical production, mitochondrial dysfunction, depletion of non-glial cells, neuronal destruction, and adjacent tissue necrosis [70].”
Amyloidosis in Alzheimer’s Disease: Pathogeny, Etiology, and Related Therapeutic Directions
Ma, C., Hong, F., & Yang, S. (2022) · Molecules · doi:10.3390/molecules27041210 · Cited by 243
Clark, P. J., Brzezinska, W. J., Thomas, M. W., Ryzhenko, N. A., Toshkov, S. A., & Rhodes, J. S. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.06.051 · Cited by 236
Danger-associated molecular patterns in Alzheimer’s disease
Venegas, C., & Heneka, M. T. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mr0416-204r · Cited by 236 · cited 1×
“When under pathological conditions, they maintain a state of chronic inflammation and progressive neuronal death [71].”
Gut Microbiota and Their Neuroinflammatory Implications in Alzheimer’s Disease
Giau, V., Wu, S., Jamerlan, A., An, S., Kim, S., & Hulme, J. (2018) · Nutrients · doi:10.3390/nu10111765 · Cited by 232
Apolipoprotein E and Alzheimer’s disease: Findings, hypotheses, and potential mechanisms
Koutsodendris, N., Nelson, M. R., Rao, A., & Huang, Y. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-030421-112756 · Cited by 231
Xiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00795-7 · Cited by 224
Self-citationApolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease
Liao, F., Yoon, H., & Kim, J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000383 · Cited by 221 · cited 2×
“Interestingly, the expression of APOE4 increased the expression of oligomers and plaque deposition, whereas APOE2 , as a protective factor, reduced the incidence of A (cid:2) accumulation and delayed the age of onset [138].”
What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?
Zott, B., Busche, M. A., Sperling, R. A., & Konnerth, A. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-061725 · Cited by 221 · cited 1×
“Functional imaging of the brains of patients with a prodrome of AD has revealed hyperactivity of neurons in the hippocampus and neocortical regions of the brain [78].”
Mora, J. S., Genge, A., Chio, A., Estol, C. J., Chaverri, D., Hernández, M., Marín, S., Mascias, J., Rodriguez, G. E., Povedano, M., et al. (2020) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2019.1632346 · Cited by 220
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219 · cited 1×
“TRx0237 is a drug approved by the FDA for the treatment of malaria, which has potential in the treatment of AD [186].”
Femminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
Feng, Q., Luo, Y., Zhang, X.-N., Yang, X.-F., Hong, X.-Y., Sun, D.-S., Li, X.-C., Hu, Y., Li, X.-G., Zhang, J.-F., et al. (2020) · Autophagy · doi:10.1080/15548627.2019.1633862 · Cited by 211
Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis
Zhu, M., Wang, X., Hjorth, E., Colas, R. A., Schroeder, L., Granholm, A.-C., Serhan, C. N., & Schultzberg, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9544-0 · Cited by 204 · cited 1×
“Some studies have indicated that the levels of RvD5, MaR1, and NPD1 in brain tissue of AD patients are decreased, and the levels of LXA4 in cerebrospinal fluid and hippocampus are also sig-nificantly decreased [114].”
Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation
Regen, F., Hellmann-Regen, J., Costantini, E., & Reale, M. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170203141717 · Cited by 204
The role of gut microbiota in pathogenesis of Alzheimer's disease
Bostanciklioğlu, M. (2019) · Journal of Applied Microbiology · doi:10.1111/jam.14264 · Cited by 200 · cited 1×
“On the other hand, intestinal flora can affect the activity of CNS through nerve, endocrine, metabolism, and immunity pathways [122–124].”
Tumor necrosis factor α Inhibition for Alzheimer’s Disease
Chang, R., Yee, K.-L., & Sumbria, R. K. (2017) · Journal of Central Nervous System Disease · doi:10.1177/1179573517709278 · Cited by 195
Zalocusky, K. A., Najm, R., Taubes, A. L., Hao, Y., Yoon, S. Y., Koutsodendris, N., Nelson, M. R., Rao, A., Bennett, D. A., Bant, J., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00851-3 · Cited by 189
Gillespie, A. K., Jones, E. A., Lin, Y.-H., Karlsson, M. P., Kay, K., Yoon, S. Y., Tong, L. M., Nova, P., Carr, J. S., Frank, L. M., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.009 · Cited by 187 · cited 1×
“Gillespie et al. [100] observed that behavior-driven gamma oscillations were reduced in a mouse model of AD before plaque formation or cognitive decline.”
Sodium Oligomannate: First Approval
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01268-1 · Cited by 187 · cited 2×
“GV-971 is a low molecu-larweightacidicoligosaccharidecompoundpreparedfrommarinebrownalgaeextractasrawmaterial, whichistheoriginalChineseandthefirstinterna-tionalnewtargetMGBAforADtreatment[126,204].”
Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s disease
Stevenson-Hoare, J., Heslegrave, A., Leonenko, G., Fathalla, D., Bellou, E., Luckcuck, L., Marshall, R., Sims, R., Morgan, B. P., Hardy, J., et al. (2023) · Brain · doi:10.1093/brain/awac128 · Cited by 183
Glucose and memory in mild senile dementia of the alzheimer type
Craft, S., Zallen, G., & Baker, L. D. (1992) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688639208402827 · Cited by 181 · cited 1×
“It has been reported that SDAT subjects demonstrated greater overall increases in blood glucose levels following glucose administration [88].”
A β 42 and A β 40: similarities and differences
Qiu, T., Liu, Q., Chen, Y., Zhao, Y., & Li, Y. (2015) · Journal of Peptide Science · doi:10.1002/psc.2789 · Cited by 180
The synapse as a treatment avenue for Alzheimer’s Disease
Peng, L., Bestard‐Lorigados, I., & Song, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01565-z · Cited by 177
Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review
Dinda, B., Dinda, M., Kulsi, G., Chakraborty, A., & Dinda, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.009 · Cited by 174 · cited 2×
“…several plant-derived secoiridoids and monoterpene iridoids, including but not limited to Oleuropein aglycone, Oleuropein, OleocanthalIri-doids, catalpol, Geniposide, Harpagoside, Loganin, have been reported to improve the cognitive impairment and neurodegenerative disorders in human [153].”
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171 · cited 1×
“Studies have shown that liraglutide has neuroprotective effects and has the potential to become a therapeutic drug for AD [201].”
Gut microbiota and pro/prebiotics in Alzheimer’s disease
Pluta, R., Ułamek-Kozioł, M., Januszewski, S., & Czuczwar, S. J. (2020) · Aging · doi:10.18632/aging.102930 · Cited by 167
Target Enzyme in Alzheimer’s Disease: Acetylcholinesterase Inhibitors
Saxena, M., & Dubey, R. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190128125912 · Cited by 162 · cited 1×
“Other studies have confirmed that severe cholinergic system damage occurs in the brain of AD patients [19], which is manifested by the damage of acetylcholine-related enzymes, mainly acetylcholinesterase (AChE) to different degrees, resulting in the reduction of ACh, which in turn leads to impaired…”
Kosel, F., Pelley, J. M. S., & Franklin, T. B. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.012 · Cited by 160 · cited 1×
“[156]”
MacPherson, K. P., Sompol, P., Kannarkat, G. T., Chang, J., Sniffen, L., Wildner, M. E., Norris, C. M., & Tansey, M. G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.02.010 · Cited by 158 · cited 1×
“XPro1595 is a selective inhibitor of sTNF [193, 194], which forms a trimer with natural sTNF, blocks the binding of TNF-(cid”
Silva, M. C., Nandi, G. A., Tentarelli, S., Gurrell, I. K., Jamier, T., Lucente, D., Dickerson, B. C., Brown, D. G., Brandon, N. J., & Haggarty, S. J. (2020) · Nature Communications · doi:10.1038/s41467-020-16984-1 · Cited by 157 · cited 1×
“Studies have shown that autophagy can reduce the load of tau in human neurons, and mTOR inhibitors, OSI-027, AZD2014, and AZD8055, could significantly reduce the content of phosphorylated and insoluble tau and improve the neurostress disorder [111].”
Recent advances in the modeling of Alzheimer’s disease
Sasaguri, H., Hashimoto, S., Watamura, N., Sato, K., Takamura, R., Nagata, K., Tsubuki, S., Ohshima, T., Yoshiki, A., Sato, K., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.807473 · Cited by 157
Sex Differences in Alzheimer’s Disease
Aggarwal, N. T., & Mielke, M. M. (2023) · Neurologic Clinics · doi:10.1016/j.ncl.2023.01.001 · Cited by 157
Animal models of Alzheimer’s disease: Applications, evaluation, and perspectives
Chen, Z.-Y., 北京大学生命科学学院膜生物学国家重点实验室, 北. 1., State Key Laboratory of Membrane Biology, C. O. L. S., & Zhang, Y. (2022) · Zoological Research · doi:10.24272/j.issn.2095-8137.2022.289 · Cited by 155 · cited 1×
“[155] Aging-basedmodel”
An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine
Khoury, R., Rajamanickam, J., & Grossberg, G. T. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617750555 · Cited by 152 · cited 1×
“TCM nursing mainly adopts acupoint massage, auricular point sticking, moxibustion, and comprehensive nursing (integrate emotion, diet, exercise, and other nursing methods) to intervene in AD patients [225, 226].”
Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer’s Disease
Chen, W. N., & Yeong, K. Y. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200214104331 · Cited by 151 · cited 1×
“[159]”
Overview of Transgenic Mouse Models for Alzheimer's Disease
Myers, A., & McGonigle, P. (2019) · Current Protocols in Neuroscience · doi:10.1002/cpns.81 · Cited by 142 · cited 1×
“With the development of therapeutics and the development of molecular biology and genetic engineering, transgenic and compound animal models have gradually become a research trend, which provides a new direction and approach for the study of AD [152].”
Mitochondrial complex I as a therapeutic target for Alzheimer's disease
Trushina, E. V., Trushin, S., & Hasan, M. F. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.003 · Cited by 141
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Burstein, A. H., Grimes, I., Galasko, D. R., Aisen, P. S., Sabbagh, M., & Mjalli, A. M. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-12 · Cited by 137 · cited 1×
“TTP-488, is an oral small molecular RAGE receptor antagonist for the treatment of mild AD, which can effectively prevent the neurotoxicity caused by RAGE-A (cid:2) interaction [182].”
Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer’s Disease
Wang, H., & Zhang, H. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00391 · Cited by 136
Amyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo
Vergara, C., Houben, S., Suain, V., Yilmaz, Z., Decker, R. D., Dries, V. V., Boom, A., Mansour, S., Leroy, K., Ando, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1953-5 · Cited by 133 · cited 1×
“In addition, Tau kinase 1 can also be activated by A (cid:2) , causing abnormal phosphorylation of microtubule-associated proteins and promoting the formation of paired helical filaments and NFTs, accelerating the development of AD [36].”
Effects of Resveratrol on the Mechanisms of Antioxidants and Estrogen in Alzheimer’s Disease
Kong, D., Yan, Y., He, X.-Y., Yang, H., Liang, B., Wang, J., He, Y., Ding, Y., & Yu, H. (2019) · BioMed Research International · doi:10.1155/2019/8983752 · Cited by 131
Mably, A. J., Gereke, B. J., Jones, D. T., & Colgin, L. L. (2017) · Hippocampus · doi:10.1002/hipo.22697 · Cited by 129
(2022) · doi:10.1038/s41467-022-34129-4 · Cited by 128
Dhapola, R., Sarma, P., Medhi, B., Prakash, A., & HariKrishnaReddy, D. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02612-6 · Cited by 123
Chen, S., Chen, S.-T., Sun, Y., Xu, Z., Wang, Y., Yao, S.-Y., Yao, W.-B., & Gao, X.-D. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101133 · Cited by 119 · cited 1×
“Studies have shown that FGF21 can alleviate the pathology of nerve injury in rats and cell models and improve cognitive performance in rats with nerve injury [199].”
Self-citationDisease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119 · cited 1×
“It can maintain microtubule structure and assist cytoplasmic transport, maintain the structure and function of nerve cell skeleton, and regulate the signal transduction of neurons [51, 52].”
Antonell, A., Lladó, A., Altirriba, J., Botta‐Orfila, T., Balasa, M., Fernández, M., Ferrer, I., Sánchez‐Valle, R., & Molinuevo, J. L. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.026 · Cited by 113 · cited 1×
“Presenilin gene-1 ( PS1 ) mutation is related to EOAD; it can protect neurons from apoptosis, and its encoded protein plays a key role in the cleavage of A (cid:2) from A (cid:2) PP in the (cid:4) -secretase [147].”
Staging of Alzheimer's disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 113
Novak, P., Zilka, N., Zilkova, M., Kovacech, B., Skrabana, R., Ondrus, M., Fialova, L., Kontsekova, E., Otto, M., & Novak, M. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.45 · Cited by 112 · cited 2×
“The vaccineisderivedfromKDNIKHVPGGGS,amino acidsequence294to305oftau,withaluminum hydroxideasanadjuvant[185].”
AlFadly, E. D., Elzahhar, P. A., Tramarin, A., Elkazaz, S., Shaltout, H., Abu-Serie, M. M., Janockova, J., Soukup, O., Ghareeb, D. A., El-Yazbi, A. F., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.012 · Cited by 105
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00678-3 · Cited by 103
Karamita, M., Barnum, C., Möbius, W., Tansey, M. G., Szymkowski, D. E., Lassmann, H., & Probert, L. (2017) · JCI Insight · doi:10.1172/jci.insight.87455 · Cited by 102 · cited 1×
“Studies have shown that sTNF can successfully cross the intact BBB, as manifested by elevated concentrations in cerebrospinal fluid and brain parenchyma [192].”
Vascular Hypothesis of Alzheimer Disease: Topical Review of Mouse Models
Scheffer, S., Hermkens, D. M. A., van der Weerd, L., de Vries, H. E., & Daemen, M. J. A. P. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.311911 · Cited by 102 · cited 1×
“[164, 165] Occlusion of bilaterial carotis communis artery with vertebral artery It simulates the pathogenesis characteristics of clinical vascular dementia well, and the physiological indicators after ischemia are relatively stable, the pathological changes are more fully defined, the stroke index…”
Griebel, G., Stemmelin, J., Lopez-Grancha, M., Boulay, D., Boquet, G., Slowinski, F., Pichat, P., Beeské, S., Tanaka, S., Mori, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54557-5 · Cited by 97 · cited 1×
“…GSK-3 (cid:2) inhibits glucose transport, glycogen synthesis, insulin secretion, and signal transduction, promotes gluconeogenesis, and leads to accumulation of A (cid:2) , hyperphosphorylation of tau, formation of NFTs, aggravation of neurotoxicity, neuronal damage, and even death [92, 93].”
Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
Bayer, T. A. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01409-2 · Cited by 94
Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease
Condello, C., & Stöehr, J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.014 · Cited by 86
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Vogt, A.-C. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 84
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2017) · Nature · doi:10.1038/nature22809 · Cited by 83
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77
α-Linolenic acid inhibits Tau aggregation and modulates Tau conformation
Desale, S. E., Dubey, T., & Chinnathambi, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.10.226 · Cited by 77
Dal Prà, I., Chiarini, A., Gui, L., Chakravarthy, B., Pacchiana, R., Gardenal, E., Whitfield, J. F., & Armato, U. (2015) · The Neuroscientist · doi:10.1177/1073858414529828 · Cited by 74 · cited 1×
“…as microglia, causing microglia to activate and produce or release pro-inflammatory factors, which in turn stimulate the surrounding astrocyte-neuronal cell population to produce higher numbers of A (cid:2) 42 oligomers, which then lead to further A (cid:2) 42 production and diffusion [32].”
Xiong, J., Li, S., Sun, Y., Zhang, X., Dong, Z., Zhong, P., & Sun, X. (2015) · Biology of Sport · doi:10.5604/20831862.1163692 · Cited by 74 · cited 1×
“Exercise can enhance the ability to resist free radicals and inhibit neurotoxicity [215].”
Tian, J., Guo, L., Sui, S., Driskill, C., Phensy, A., Wang, Q., Gauba, E., Zigman, J. M., Swerdlow, R. H., Kroener, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6278 · Cited by 72 · cited 1×
“:3) causes hippocampal synaptic AD-like stress and memory impairment [104].”
Alzheimer's disease: Innate immunity gone awry?
VanItallie, T. B. (2017) · Metabolism · doi:10.1016/j.metabol.2017.01.014 · Cited by 67 · cited 1×
“However, the causal relationship between them is still a controversial issue [69].”
Haig, G. M., Bain, E., Robieson, W., Baker, J. D., & Othman, A. A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15010093 · Cited by 65 · cited 1×
“-7nAChRs agonist developed by AbbVie Company for the treatment of mild or moderate AD, which is currently in phase II clinical trial [175].”
Alzheimer’s disease and the autophagic-lysosomal system
Chung, K. M., Hernández, N., Sproul, A. A., & Yu, W. H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.017 · Cited by 63
Can inflammation be resolved in Alzheimer’s disease?
Zhu, M., Wang, X., Sun, L., Schultzberg, M., & Hjorth, E. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418791107 · Cited by 62
Gut Microbiota and Alzheimer’s Disease: How to Study and Apply Their Relationship
Nguyen, N. M., Cho, J., & Lee, C.-H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044047 · Cited by 62 · cited 1×
“With the in-depth study of the relationship between intestinal flora and AD, more and more evidence shows that intestinal flora interacts with the CNS, which is vividly called the “microbe-gut-brain axis” (MGBA) [120, 121] (Fig.”
Senescence-accelerated Mice (SAMs) as a Model for Brain Aging and Immunosenescence.
Shimada, A., & Hasegawa‐Ishii, S. (2011) · Europe PMC (PubMed Central) · Cited by 62
Porrini, V., Lanzillotta, A., Branca, C., Benarese, M., Parrella, E., Lorenzini, L., Calzà, L., Flaibani, R., Spano, P., Imbimbo, B. P., et al. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.029 · Cited by 60
Scali, C., Prosperi, C., Vannucchi, M. G., Pepeu, G., & Casamenti, F. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00075.x · Cited by 58
Utilizing zebrafish and okadaic acid to study Alzheimer’s disease
Williams, F., & Köehler, D. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.237111 · Cited by 58
Kumar, R., Nordberg, A. K., & Darreh‐Shori, T. (2015) · Brain · doi:10.1093/brain/awv318 · Cited by 57
The microbiome: A target for Alzheimer disease?
Seo, D.-O., Boros, B. D., & Holtzman, D. M. (2019) · Cell Research · doi:10.1038/s41422-019-0227-7 · Cited by 56 · cited 1×
“On the other hand, intestinal flora can affect the activity of CNS through nerve, endocrine, metabolism, and immunity pathways [122–124].”
Zhou, R., Yang, G., & Shi, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713605114 · Cited by 53
Hippocampus ghrelin receptor signaling promotes socially-mediated learned food preference
Hsu, T. M., Noble, E. E., Reiner, D. J., Liu, C. M., Suarez, A. N., Konanur, V. R., Hayes, M. R., & Kanoski, S. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.039 · Cited by 53
Jeong, Y.-O., Shin, S. J., Park, J. Y., Ku, B. K., Song, J. S., Kim, J.-J., Jeon, S. G., Lee, S. M., & Moon, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061800 · Cited by 52
N-AS-triggered SPMs are direct regulators of microglia in a model of Alzheimer’s disease
Lee, J. Y., Han, S. H., Park, M. H., Song, I.-S., Choi, M.-K., Yu, E., Park, C.-M., Kim, H.-J., Kim, S. H., Schuchman, E. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16080-4 · Cited by 52 · cited 1×
“In vitro , studies have confirmed that PMs can improve the survival rate of neurons and increase the phagocytosis ability of microglia to A (cid:2) [116].”
Buechler, J., & Salinas, P. C. (2018) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2018.00038 · Cited by 51 · cited 1×
“The mechanism may be related to the decreased expression of low-density lipoprotein receptor-related protein-6 (LRP6) in the Wnt signaling pathway [95].”
N-terminal Truncation of Microtubule Associated Protein Tau Dysregulates its Cellular Localization
Paholikova, K., Salingova, B., Opattova, A., Skrabana, R., Majerova, P., Zilka, N., Kovacech, B., Zilkova, M., Barath, P., & Novak, M. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140996 · Cited by 50 · cited 1×
“AADvac1isavaccineagainstpathologically-modifiedtau,whichcantriggeranimmune responsetoeliminatethepathologically-modified formderivedfromtheN-terminaltruncatedfrag-mentproducedbythecleavageoftau[184].”
Cummings, J. L., & Zhong, K. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.190 · Cited by 50 · cited 1×
“Through a series of clinical studies [227], it is found that it can improve cognitive function, mental symptoms, and daily living ability.”
Alzheimer disease immunotherapeutics: Then and now
Jindal, H., Bhatt, B., Sk, S., & Singh Malik, J. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.970959 · Cited by 50 · cited 1×
“TCM nursing mainly adopts acupoint massage, auricular point sticking, moxibustion, and comprehensive nursing (integrate emotion, diet, exercise, and other nursing methods) to intervene in AD patients [225, 226].”
Shimada, H., Ataka, S., Tomiyama, T., Takechi, H., Mori, H., & Miki, T. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000330017 · Cited by 50 · cited 1×
“Furthermore, Shimada et al. [44] found that patients with mutations in the APP-E693 (cid:4) gene, associated with the formation of insoluble amyloid fibers, also commonly have clinical syndromes very similar to AD but not related to amyloid plaque deposition in the brain.”
Amyloid-β toxicity modulates tau phosphorylation through the PAX6 signalling pathway
Zhang, Y., Zhang, Y., Aman, Y., Ng, C. T., Chau, W. H., Zhang, Z., Yue, M., Böhm, C., Jia, Y., Li, S., et al. (2021) · Brain · doi:10.1093/brain/awab134 · Cited by 50 · cited 1×
“Another studyfirstshowedthatPax6,akeytranscriptionfactor inneurodevelopment,wasrelativelystationarywhen therewasnostress,butitsexpressionwaselevatedin bothmousemodelsandthebrainsofADpatients [61].”
Is ‘friendly fire’ in the brain provoking Alzheimer’s disease?
Abbott, A. (2018) · Nature · doi:10.1038/d41586-018-04930-7 · Cited by 45
Gruendler, R., Hippe, B., Sendula Jengic, V., Peterlin, B., & Haslberger, A. G. (2020) · Molecules · doi:10.3390/molecules25246018 · Cited by 45
Acetylcholinesterase Modulates Presenilin-1 Levels and γ-Secretase Activity
Campanari, M.-L., García-Ayllón, M.-S., Belbin, O., Galcerán, J., Lleó, A., & Sáez-Valero, J. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140426 · Cited by 40 · cited 1×
“…have proved that cholinergic nerve imbalance can accelerate A (cid:2) deposition, AChE binds directly to presenilin-1 (PS1), a key enzyme site in A (cid:2) production, and significantly enhances its expression, thereby increasing A (cid:2) levels and accelerating cognitive dysfunction [21, 22].”
The Vascular-Immune Hypothesis of Alzheimer’s Disease
Mehta, R. I., & Mehta, R. I. (2023) · Biomedicines · doi:10.3390/biomedicines11020408 · Cited by 37
Alzheimer's disease: 120 years of research and progress
Ciurea, V., Covache-Busuioc, R.-A., Mohan, A. G., Costin, H. P., & Voicu, V. A. (2023) · Journal of Medicine and Life · doi:10.25122/jml-2022-0111 · Cited by 37
Lecanemab slows Alzheimer's disease: hope and challenges
Mead, S., & Fox, N. C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00529-4 · Cited by 36
Shuaib, S., & Goyal, B. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1291363 · Cited by 35
Li, W., Sun, L., Yue, L., & Xiao, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1120495 · Cited by 34
Qin, L., Chong, T., Rodriguez, R., & Pugazhenthi, S. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160401114751 · Cited by 32
Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update
Khan, S. S., Khatik, G. L., & Datusalia, A. K. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411083922 · Cited by 31
Mitochondrial mechanisms in Alzheimer’s disease: Quest for therapeutics
Kalani, K., Chaturvedi, P., Chaturvedi, P., Verma, V. K., Lal, N., Awasthi, S. K., & Kalani, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103547 · Cited by 30
Cavanagh, C., & Wong, T. P. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.01.003 · Cited by 29
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease
Lee, D., Clark, E. D., Antonsdottir, I. M., & Porsteinsson, A. P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2195539 · Cited by 28
Maleki, A. F., Cisbani, G., Plante, M.-M., Préfontaine, P., Laflamme, N., Gosselin, J., & Rivest, S. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01893-3 · Cited by 26
Tau mRNA 3′UTR-to-CDS ratio is increased in Alzheimer disease
García‐Escudero, V., Gargini, R., Martín-Maestro, P., García, E., García‐Escudero, R., & Ávila, J. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.07.007 · Cited by 25 · cited 2×
“However, when tau is misfolded, they aggregate to form insoluble paired helical filaments and straight filaments, resulting in the formation of intraneural fibrous deposits which are called NFTs [53].”
Alzheimer’s Disease Genetics: A Dampened Microglial Response?
Chatila, Z. K., & Bradshaw, E. M. (2021) · The Neuroscientist · doi:10.1177/10738584211024531 · Cited by 25
Cazzola, M., Centanni, S., & Donner, C. F. (1998) · Pulmonary Pharmacology & Therapeutics · doi:10.1006/pupt.1999.0174 · Cited by 25
Rožanković, P. B., Rožanković, M., Badžak, J., Stojić, M., & Sporiš, I. Š. (2021) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000285 · Cited by 24 · cited 1×
“It is currently used in the clinical treatment of moderate or severe AD [172].”
Vitamin D Attenuates Alzheimer-like Pathology Induced by Okadaic Acid
Pan, Y., Zhang, Y., Liu, N., Lu, W., Yang, J., Li, Y., Liu, Z., Wei, Y., Lou, Y., & Kong, J. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00812 · Cited by 23
Zeng, H., Xu, L., Zou, Y., & Wang, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111864 · Cited by 23 · cited 1×
“[160] Okadaic acid It can cause degeneration and necrosis of nerve cells, promote the formation of abnormal phosphorylated tau in the brain, A (cid:2) accumulation, resulting in pathological features like AD.”
C-reactive protein and risk of Alzheimer's disease
Zhang, Z., Wang, M., & Liu, X. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.010 · Cited by 23
The oxidatively damaged DNA and amyloid-β oligomer hypothesis of Alzheimer's disease
Sanders, O. D., Rajagopal, L., & Rajagopal, J. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.08.019 · Cited by 21
MacPherson, K. P., Eidson, L. N., Houser, M. C., Weiss, B. E., Gollihue, J. L., Herrick, M. K., Rodrigues, M. E. D. S., Sniffen, L. J., Weekman, E. M., Hamilton, A. M., et al. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.895017 · Cited by 20
Impact of deprescribing AChEIs on aggressive behaviors and antipsychotic prescribing
Niznik, J. D., Zhao, X., He, M., Aspinall, S. L., Hanlon, J. T., Nace, D. A., Thorpe, J. M., & Thorpe, C. T. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12054 · Cited by 19 · cited 1×
“Acetylcholinesterase inhibitors (AChEIs) could restore the function of the cholinergic system by blocking the function of AChE and increasing the survival of ACh in the synaptic cleft [170].”
Self-citationJiao, F., Jiang, D., Li, Y., Mei, J., Wang, Q., & Li, X. (2022) · Cells · doi:10.3390/cells11203201 · Cited by 17 · cited 1×
“It is now generally accepted that soluble A (cid:2) oligomers are more toxic than A (cid:2) cellulose [34].”
Clark, I. A., & Vissel, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1618710 · Cited by 16
Zhang, J., Liu, Y., Li, L.-X., Li, K., Chen, J., & Wang, F. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107934 · Cited by 16 · cited 1×
“…system functions including altered distribution or activity of neurotransmitter receptors and related signaling molecules, disruption of intracellular Ca 2 + homeostasis, impaired axon transport, and mitochondrial function, the release of inflammatory factors, and tau hyperphosphorylation [48, 49].”
Self-citationSavolainen, K., Ihalainen, J. A., Jalkanen, A. J., & Forsberg, M. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5130-2 · Cited by 13 · cited 1×
“…of Ca 2 + and the activation of the second messenger system, which further lead to the release of a variety of neurotransmitters including glutamate and (cid:4) -aminobutyric acid, so as to regulate the abnormal activity of the nervous system in the brain and play a therapeutic effect on AD [174].”
Wilson, C., Rogers, J., Chen, F., Li, S., Adlard, P. A., Hannan, A. J., & Renoir, T. (2021) · Brain Structure and Function · doi:10.1007/s00429-021-02283-y · Cited by 12 · cited 1×
“Moreover, exercise can increase the expression of neurotrophic factors in hippocampus, cerebral cortex, and other parts, promote angiogenesis, facilitate the occurrence of hippocampal nerves and synapses, strengthen the connection of neural networks, and improve synaptic plasticity [6, 214].”
Fang, L., Shen, S., Liu, Q., Liu, Z., & Zhao, J. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128976 · Cited by 11
Li, Z., Ma, H., Wang, M., & Qian, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1036120 · Cited by 11
What is the role of lipids in prion conversion and disease?
Conceição, C. A., de Lemos, G. A., Barros, C. A., & Vieira, T. C. R. G. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1032541 · Cited by 10 · cited 1×
“Studies have shown that A (cid:2) can be transmitted in the brain through a pathogenic conformation similar to PrPSc [101].”
Wang, Y., Wang, M., Zeng, X., Liu, Y.-H., & Wang, Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220775 · Cited by 9
Self-citation
Research works printed but not linked: 8
- Hedia, 2015, Modeling the interaction between β-amyloid aggregates and choline acetyltransferase activity and its relation with cholinergic dysfunction through two-enzyme/two-compartment model, Comput Math Methods Med, 2015, 923762
- Wang, 2020, Research progress of Wnt/LRP6 signaling pathway on synaptic function in Alzheimer′s disease, China Med Herald, 17, 33
- Yu, 2022, Advances in immunotherapy targeting Aβ and Tau in Alzheimer’s disease, Chinese J Immunolo, 38, 626
- Garcia-Escudero, 2017, Tau mRNA 3’UTR-to-CDS ratio is increased in Alzheimer disease, Neurosci Lett, 655, 101, 10.1016/j.neulet.2017.07.007 · DOI
- Qu, 2022, Treatment of Alzheimer’s disease with Traditional Chinese Medicine based on β-amyloid: A review, Chinese J Exp Tradit Med Formulae, 28, 231
- Hua, 2017, A review on treating Alzheimer’s disease in TCM, Clin J Chinese Med, 9, 139
- Gao, 2020, Exploration on medication rules in treatment for Alzheimer’s disease with Chinese materia medica based on data mining, J Hunan Univ Chinese Med, 40, 1515
- Shen, 2022, Regulatory effect ofdietary nutrients on the pathogenesis of Alzheimer’s disease, J Public Health Prev, 33, 1
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Wang, J., Meng, X., Jialun, Y., Tang, Y., Zeng, F., Wang, Y., Chen, Z., Chen, D., Zou, R., & Liu, W. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04350-w · Cited by 15
Self-citationHua, Z., Zhou, N., Zhou, Z., Fu, Z., Guo, R., Akogo, H. Y., Yang, J.-Y., Yu, M., Jiang, Y., Lan, S., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04555-4 · Cited by 12
Liu, Y., Song, S., Li, X., Wang, J., Bao, Y., Wang, X., Lian, L., Liu, X., & Ma, W. (2024) · Pharmaceuticals · doi:10.3390/ph17091231 · Cited by 13
“AD is mostly due to symptoms of near-memory impairment, and abnormalities in memory, recognition, expression, emotion, and personality gradually increase [3].”
BackgroundAlves, R. L., Gonçalves, A., Voytyuk, I., & Harrison, D. C. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115234 · Cited by 11
Metadata
- Authors
- Xia, Z.-D., Ma, R.-X., Wen, J.-F., Zhai, Y.-F., Wang, Y.-Q., Wang, F.-Y., Liu, D., Zhao, X.-L., Sun, B., Jia, P., & Zheng, X.-H.
- Affiliations
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Northwest University, Xi’an, PR China
- Northwest University (CN)
- Corresponding author
- Jia, Pu
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2023-08-15
- Volume
- 94
- Issue
- 4
- Pages
- 1265-1301
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W4383558173
- Cited by
- 19
- References
- 206
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 6 · 2023: 1
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, pathogenesis
- MeSH terms
- Alzheimer Disease, Animals, Quality of Life, Neurodegenerative Diseases, Models, Animal, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.